

Aggregate revenue performance

%	CAGR FY21-25	CAGR FY25-27E
Kaynes	59	57
Avalon	12	28
Cyient DLM	25	22
Syrma SGS	44	32
Data Patterns	33	25
Dixon	57	31
Amber	35	20
Aggregate	48	31
Aggregate (ex Dixon & Amber)	36	37

EBITDA performance (%)

Growth %	CAGR FY21-25	CAGR FY25-27E
Kaynes	78	61
Avalon	14	40
Cyient DLM	33	34
Syrma SGS	31	34
Data Patterns	31	25
Dixon	51	33
Amber	36	27
Aggregate	42	35
Aggregate (ex Dixon & Amber)	38	42

Scaling up for global leadership with strong order visibility and capacity growth

India's electronics manufacturing services (EMS) industry continues to experience a robust growth trajectory, driven by a surge in global orders, growing export prospects and strong traction across segments. Key catalysts of this momentum include a growing influx of orders in high-margin sectors, reinforced global positioning and the consistent competitive advantage in the production of complex products. Our coverage universe consists of Kaynes Technology (KAYNES), Avalon Technologies (AVALON), Syrma SGS Technology (SYRMA), Cyient DLM (CYIENTDL), Data Patterns (DATAPATT), Dixon Technologies (DIXON), and Amber Enterprises (AMBER).

- EMS companies are witnessing rising order inflows from high-margin segments like aerospace, industrials, automotive, and critical infrastructure, driven by higher work content, better execution visibility, and an improving product mix.
- India's electronics demand is fueled by multiple macro tailwinds such as increasing investments in security & safety solutions, innovation of new technologies (AI, EVs etc) and infrastructure modernization. Low penetration of consumer electronics and growth in disposable incomes will boost growth prospects for the EMS industry. Increasing participation from domestic companies as well as MNCs and their supply chains positions the Indian EMS industry for steady high-growth opportunities.
- Capacity expansion plans by domestic EMS players, complemented by government-led initiatives like the PLI scheme, should boost growth opportunities. These efforts are helping to create a robust domestic ecosystem such as semiconductors, electronic components, and high-value electronics manufacturing, further strengthening India's position as a competitive global manufacturing hub in the coming years.
- Accordingly, we believe that the EMS industry will maintain its earnings growth momentum, aided by expanding global opportunities for EMS companies, which should result in a robust order book and capacity expansions in the long run. We expect our EMS coverage companies to achieve a CAGR of 31%/35%/48% in revenue/EBITDA/adj. PAT over FY25-27.

Promising demand trends across segments to drive order book growth

- EMS companies are witnessing increasing order inflows across various segments, with particularly strong traction in high-margin sectors such as aerospace, industrials, automotive, and critical infrastructure applications. They are also focusing on gaining a higher wallet share and an improved product mix.
- These segments are benefiting from higher work content and improved execution visibility, which is translating into enhanced margins and a stronger growth potential for the industry.
- The aggregate order book (excluding Amber and Dixon) saw a stable growth rate of ~23% YoY and stood at INR163b as of Mar'25. This growth was driven by companies that are consistently witnessing strong traction in pipeline, led by client additions and completion of prototype/first article work for new clients with the expectation of batch production to start in FY26.
- **KAYNES'** order inflows remained robust at INR15.3b as of Mar'25, driving 60% YoY/9% QoQ growth in the order book to ~INR66b as of Mar'25. This growth was primarily supported by the addition of margin-accretive orders across aerospace, industrial, and automobile segments. Notably, the average monthly order inflow improved to INR5.1b in 4QFY25 from INR4.2b in 3QFY25.

Research Analyst: **Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

Research Analyst: **Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **AVALON** witnessed growth across all business segments, with the total order book standing at INR28.8b in Mar'25, the short-term order book (executable within 14 months) at INR17.6b (up 29% YoY/11% QoQ) and the longer executable order book (from 14 months up to three years) at INR11.23b (up 18% YoY). Growth in the order book was led by recent order wins, which include projects in backup power systems, transmission systems, aerospace cabin products, and locomotive engine systems.
- **CYIENT DLM** delivered strong revenue and EBITDA growth despite the order book remaining under pressure (consolidated order book continued to decline by 12% YoY/11% QoQ to INR19b) as consumption growth by major clients outpaced new order growth. However, management anticipates strong order traction in the North American market going forward, supported by ongoing discussions with three big global players.
- **DATAPATT**'s order book stands at INR7.3b as of 31st Mar'25 and INR8.6b till date, and about 70-80% of the total order book is expected to be executed in FY26. Additional contracts under Brahmos are expected to materialize in the near term, and the company looks to finalize a contract for Ashwini LLTR radar within the next three to six months.
- Smartphone business visibility continues to improve for **Dixon**, with a healthy order book, supported by its anchor customer ramping up export volumes to North America. Additionally, order inflows from Xiaomi and Longcheer have seen a significant uptick this quarter, while demand from Intel and Infinix remains robust, further strengthening Dixon's smartphone manufacturing pipeline.
- **Strong and diversified order inflows across key sectors position EMS companies for stable growth in FY26, with robust execution visibility and rising export opportunities driving the momentum.**

Expanding capacities to meet growing order book

- India's electronics demand is fueled by multiple macro tailwinds such as increasing investments in security & safety solutions, innovation of new technologies (AI, EVs, etc.) and infrastructure modernization. Low penetration of consumer electronics and rising disposable incomes will boost growth prospects for the EMS industry.
- Growing participation from domestic companies as well as MNCs and their supply chains positions the Indian EMS industry for stable high-growth opportunities.
- The ambitious capacity augmentation plans of indigenous EMS players to capitalize on favorable government policies will support growth for the Indian EMS industry in the coming years.
- With the construction of OSAT facilities by **KAYNES** in Sanand and HDI PCB facilities in Chennai on track, the trials for its chips in the OSAT facility are scheduled to begin in 2Q/3QFY26 and production should start by 4QFY26.
- **Avalon** is investing INR400–500m in FY26 to set up a new export-oriented facility in Chennai and a domestic plant near (~30km) its existing Tamil Nadu unit. These expansions are aimed at catering to rising demand from European and GCC markets, currently catering to Japanese firms. Concurrently, the company is also developing new products across key industry verticals to strengthen its portfolio and enhance its market presence.

- As **SYRMA SGS** continues to prioritize growth in the automotive and industrial segments, it has operationalized a new manufacturing facility in Pune. This will help the company establish its presence in the western region and strengthen its printed circuit board assembly (PCBA) capabilities. SYRMA has installed two lines at the facility so far and may proceed with brownfield expansion as needed.
- **Dixon** is well-positioned to scale up operations and enhance its global competitiveness. It is executing multiple expansion strategies to meet growing customer demand and strengthen its position across key segments, including constructing a 1m sq. ft. mobile manufacturing facility with dedicated capacity for anchor clients and a display module plant with HKC, with plans to double its capacity in later phases.
- In line with its growth aspirations, **Amber** plans to incur a capex of INR5b across the RAC, railway and electronics divisions. Under the electronic component manufacturing scheme (ECMS), the company will file for a capex project of ~INR30b over the next five years. After government and state incentives (up to 65% reimbursement), net capex is expected to be around 30-35%.
- These capacity expansion plans by major EMS players, complemented by government-led initiatives like the PLI scheme, are expected to augment the growing growth opportunities.
- These initiatives are fostering the creation of a strong domestic ecosystem for semiconductors, electronic components, and high-value electronics manufacturing, further enhancing India's competitiveness as a global manufacturing hub in the years ahead.

Healthy growth continues with margin expansion

- The aggregate order book for the sector grew 23% YoY to INR163b in FY25 (excluding Dixon and Amber), reflecting robust demand across key players. KAYNES led with 60% YoY growth, followed by Avalon/SYRMA at +29/+19%, while DATAPTT/CYIENT experienced a decline of 33%/13% YoY.
- Aggregate revenue surged ~84% YoY to INR586b in FY25 (excl. Dixon and Amber, it was up 30% YoY). Dixon led with 2.2x YoY growth (driven by its mobile segment), followed by AMBER at 48% YoY, led by rising demand in consumer durables and electronics; and Kaynes at 51% YoY (led by industrials up by 76%). DATAPATT/AVALON/CYIENTDL/SYRMA reported revenue growth of 36%/27%/27%/20% YoY.
- Aggregate EBITDA grew 73% YoY to INR35b in FY25, with margins contracting 40bp YoY to 6% (due to a 380bp decline in DATAPATT). While there was a marginal contraction in overall margins, EBITDA grew for all companies, with DIXON reporting EBITDA growth of 2.2x to INR15b, followed by 77% growth for AVALON, 62% for KAYNES, 55% for AMBER, 52% for CYIENTDLM, 31% for SYRMA and 24% for DATAPATT.
- DATAPATT reported an EBITDA margin decline of ~380bp as management took up low-margin strategic contracts. All other EMS companies in our coverage witnessed margin expansion in FY25, led by a favorable product mix and operational efficiencies.

Valuation and view: Uptrend likely to continue for EMS industry

- We estimate a 31% CAGR in aggregate revenue of our EMS coverage companies over FY25-27E, aided by robust order flows, capacity additions, ramp-up of existing and new plants, and development of new products across key industry verticals (such as rail, industrial infrastructure, clean energy, and communications).
- Consequently, combined EBITDA margin is likely to expand over FY25-27, fueled by favorable operating leverage. Accordingly, EBITDA is expected to register a CAGR of ~35% over FY25-27E.
- We reiterate our **BUY** rating on **KAYNES (TP:7300)**, **AVALON (TP: 1030)**, **CYIENTDL (TP: 600)**, **SYRMA (TP: 630)**, **DIXON (TP:20500)** and **AMBER (TP: 7600)** and our **Neutral** stance on **DATAPATT (TP:2530)**.

Exhibit 1: Comparative valuation

Peers	CMP (INR)	TP (INR)	Mcap (INR b)	EPS			P/E			RoE (%)			RoCE (%)		
				FY25	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Kaynes	5,612	7,300	360	46	84	132	123	67	42	11.02	17.22	22.32	11.5	15.4	21.6
Avalon	841	1030	56	10	16	25	88	52	33	10.9	16.0	20.9	10.1	14.3	19.7
Cyient DLM	446	600	35	9	15	22	48	29	20	8.0	12.0	15.1	9.1	11.7	15.0
Syrma SGS	511	630	96	10	15	21	53	35	25	10.2	13.9	17.1	10.2	12.9	15.9
Data Pattern	2935	2,530	164	40	50	64	74	59	46	15.7	16.9	18.3	16.3	17.5	18.7
Dixon	14,004	20,500	846	117	169	242	120	83	58	30.0	29.1	31.1	38.6	35.8	36.9
Amber	6,422	7,600	218	72	104	160	89	62	40	11.2	14.3	18.6	11.1	12.4	15.1

Source: MOFSL

Exhibit 2: Order book jumped 23% YoY in FY25

(INR m)	FY21	FY22	FY23	FY24	FY25	Change YoY (%)
Kaynes	6,705	15,166	26,482	41,152	65,969	60
Avalon	6,346	8,579	12,310	13,660	17,610	29
Cyient DLM	9,061	12,029	24,325	21,705	19,061	-12
Syrma SGS	20,000	25,000	30,000	45,000	53,500	19
Data Patterns	4,980	4,760	9,241	10,831	7,298	-33
Aggregate	47,092	65,534	1,02,358	1,32,348	1,63,438	23

Source: MOFSL

Exhibit 3: Aggregate revenue for EMS is likely to clock 31% CAGR over FY25-27

(INR m)	FY21	FY22	FY23	FY24	FY25	Change YoY (%)	CAGR FY21-25 (%)	FY26E	FY27E	CAGR FY25-27 (%)
Kaynes	4,206	7,062	11,261	18,046	27,218	51	59	42,913	67,047	57
Avalon	6,905	8,407	9,447	8,672	10,981	27	12	14,056	17,992	28
Cyient DLM	6,280	7,205	8,320	11,919	15,196	27	25	18,387	22,800	22
Syrma SGS	8,858	12,667	20,484	31,538	37,862	20	44	51,113	66,447	32
Data Patterns	2,240	3,109	4,535	5,198	7,084	36	33	8,876	11,139	25
Dixon	64,482	1,06,971	1,21,920	1,76,909	388,601	120	57	532,357	671,868	31
Amber	30,305	42,064	69,271	67,293	99,730	48	35	116,928	143,332	20
Aggregate	1,23,276	1,87,485	2,45,238	3,19,575	586,672	84	48	784,630	1,000,625	31
Aggregate (sans Dixon & Amber)	28,489	38,450	54,047	75,373	98,340	30	36	135,345	185,425	37

Source: MOFSL

Exhibit 4: EBITDA for our EMS coverage is expected to post ~35% CAGR over FY25-27

(INR m)	FY21	FY22	FY23	FY24	FY25	Change YoY (%)	CAGR FY21-25 (%)	FY26E	FY27E	CAGR FY25-27 (%)
Kaynes	409	937	1,683	2,542	4,107	62	78	6,651	10,619	61
Avalon	662	975	1,128	626	1,105	77	14	1,588	2,177	40
Cyient DLM	460	840	878	1,110	1,452	31	33	1,949	2,622	34
Syrma SGS	1,016	1,287	1,878	1,984	3,021	52	31	4,089	5,449	34
Data Patterns	920	1,410	1,718	2,217	2,750	24	31	3,364	4,288	25
Dixon*	2,866	3,790	5,121	6,976	15,076	116	51	20,196	26,600	33
Amber*	2,203	2,754	4,180	4,919	7,634	55	36	9,579	12,410	27
Aggregate	8919	12879	18346	22990	35145	73	42	47417	64166	35
Aggregate (excluding Dixon & Amber)	3,466	5,449	7,285	8,478	12,435	47	38	17,642	25,156	42

Source: MOFSL

Exhibit 5: EBITDA margin trend

%	FY21	FY22	FY23	FY24	FY25	Change YoY	FY25 vs FY21	FY26E	FY27E	FY27 vs FY25
Kaynes	10	13	15	14	15	101	537	15	16	75
Avalon	10	12	12	7	10	285	48	11	12	204
Cyient DLM	7	12	11	9	10	24	224	11	12	195
Syrma SGS	11	10	9	6	8	169	-349	8	8	22
Data Patterns	41	45	38	43	39	-382	-225	38	39	-32
Dixon*	4	4	4	4	4	-6	-57	4	4	8
Amber*	7	7	6	7	8	35	39	8	9	100
Aggregate	7	6	7	6.6	6	-38	-93	6.0	6.4	42
Aggregate (excluding Dixon & Amber)	12.2	14.2	13.5	11.2	12.6	140	48	13.0	13.6	92

Source: MOFSL

Exhibit 6: Adj. PAT for our EMS coverage is expected to see ~48 CAGR over FY25-27

(INR m)	FY21	FY22	FY23	FY24	FY25	Change YoY (%)	CAGR FY21-25 (%)	FY26E	FY27E	CAGR FY25-27 (%)
Kaynes	97	417	952	1,834	2,934	60	134	5,351	8,482	70
Avalon	215	632	525	280	634	127	31	1,062	1,575	58
Cyient DLM	118	398	317	612	739	21	58	1,209	1,747	54
Syrma SGS	630	722	1,193	1,087	1,719	58	29	2,594	3,681	46
Data Patterns	556	940	1,240	1,817	2,218	22	41	2,785	3,580	27
Dixon*	1,598	1,901	2,555	3,678	7,059	92	45	10,162	14,557	44
Amber*	816	1,092	1,572	1,329	2,436	83	31	3,532	5,421	49
Aggregate	4200	6471	9129	11985	17740	48	43	26695	39043	48
Aggregate (sans Dixon & Amber)	1,617	3,108	4,227	5,630	8,245	46	50	13,001	19,065	52

Source: MOFSL

Exhibit 7: Aggregate order book increased 23% YoY in 4QFY25

(INR m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Change % YoY	Change % QoQ
Kaynes	26,482	30,004	34,618	37,890	41,152	50,386	54,228	60,471	65,969	60	9
Avalon	12,310	11,060	12,440	12,750	13,660	14,610	14,850	15,940	17,610	29	10
Cyient DLM	24,325	24,997	22,866	22,949	21,705	21,267	19,790	21,429	19,061	-12	-11
Syrma SGS	30,000	35,000	38,000	45,000	45,000	45,000	48,000	53,000	53,500	19	1
Data Patterns	9,241	9,671	10,033	9,629	10,831	10,171	9,714	10,947	7,298	-33	-33
Aggregate (sans Dixon and Amber)	102,358	110,732	117,957	128,218	132,348	141,434	146,582	161,787	163,438	23	1

Source: MOFSL

Exhibit 8: Aggregate revenue grew 71%YoY in 4QFY25

(INR m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Change % YoY
Kaynes	3,645	2,972	3,608	5,093	6,373	5,040	5,721	6,612	9,845	54
Avalon	2,718	2,351	2,010	2,143	2,168	1,995	2,750	2,809	3,428	58
Cyient DLM	2,774	2,171	2,918	3,210	3,618	2,579	3,895	4,442	4,281	18
Syrma SGS	6,795	6,013	7,117	7,067	11,341	11,599	8,327	8,692	9,244	-18
Data Patterns	1,851	897	1,083	1,395	1,823	1,041	910	1,170	3,962	117
Dixon	30,655	32,715	49,432	48,183	46,580	65,798	115,341	104,537	102,925	121
Amber	30,026	17,020	9,271	12,948	28,055	24,013	16,847	21,333	37,537	34
Aggregate	78,464	64,139	75,440	80,038	99,958	112,064	153,791	149,595	171,221	71
Aggregate (sans Dixon and Amber)	17,783	14,404	16,737	18,908	25,323	22,253	21,603	23,725	30,759	21

Source: MOFSL

Exhibit 9: Aggregate EBITDA jumped 75% YoY in 4QFY25

(INR m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Change % YoY
Kaynes	593	403	488	699	952	669	821	940	1,679	76
Avalon	411	162	126	165	172	44	301	346	414	141
Cyient DLM	319	200	235	294	380	200	316	361	574	51
Syrma SGS	575	369	490	388	737	446	710	791	1,075	46
Data Patterns	734	278	408	600	930	372	343	540	1,495	61
Dixon	1,563	1,319	1,989	1,844	1,825	2,479	4,264	3,905	4,428	143
Amber	2,035	1,319	596	785	2,219	1,962	1,137	1,587	2,947	33
Aggregate	6,229	4,050	4,332	4,776	7,215	6,171	7,893	8,471	12,611	75
Aggregate (barring Dixon and Amber)	2,631	1,412	1,747	2,147	3,172	1,730	2,492	2,979	5,236	65

Source: MOFSL

Exhibit 10: Aggregate EBITDA margin trend (%)

	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Change YoY
Kaynes	16.3	13.5	13.5	13.7	14.9	13.3	14.4	14.2	17.1	211
Avalon	15.1	6.9	6.3	7.7	7.9	2.2	11.0	12.3	12.1	413
Cyient DLM	11.5	9.2	8.1	9.2	10.5	7.8	8.1	8.1	13.4	290
Syrma SGS	8.5	6.1	6.9	5.5	6.5	3.8	8.5	9.1	11.6	513
Data Patterns	39.6	31.0	37.6	43.0	51.0	35.7	37.7	46.2	37.7	-1330
Dixon	5.1	4.0	4.0	3.8	3.9	3.8	3.7	3.7	4.3	39
Amber	6.8	7.8	6.4	6.1	7.9	8.2	6.8	7.4	7.9	-6
Aggregate	7.9	6.3	5.7	6.0	7.2	5.5	5.1	5.7	7.4	15
Aggregate (excluding Dixon and Amber)	14.8	9.8	10.4	11.4	12.5	7.8	11.5	12.6	17.0	450

Source: MOFSL

Exhibit 11: Aggregate Adj. PAT grew 60% YoY in 4QFY25

(INR m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Change % YoY
Kaynes	412	246	323	452	813	508	602	665	1,162	43
Avalon	227	71	73	66	71	-23	175	240	243	244
Cyient DLM	126	54	147	184	227	106	155	168	310	36
Syrma SGS	423	285	297	155	349	193	362	509	654	87
Data Patterns	554	258	338	510	711	328	303	447	1,141	60
Dixon	806	688	1,073	964	952	1,337	2,143	1,712	1,845	94
Amber	1,040	456	-69	-5	947	724	192	359	1,160	23
Aggregate	3,588	2,059	2,181	2,327	4,070	3,172	3,932	4,099	6,516	60
Aggregate (excluding Dixon, and Amber)	1,741	914	1,177	1,367	2,171	1,112	1,597	2,029	3,510	62

Source: MOFSL; *Loss to profit

Keynes – Financials & Valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	3,682	4,206	7,062	11,261	18,046	27,218	42,913	67,047
Change (%)	1.1	14.2	67.9	59.4	60.3	50.8	57.7	56.2
RM Cost	2,417	2,861	4,894	7,801	13,299	18,997	30,683	48,073
Employees Cost	424	459	602	771	1,028	1,781	2,360	3,621
Other Expenses	428	477	629	1,006	1,178	2,333	3,219	4,734
Total Expenditure	3,269	3,797	6,126	9,578	15,505	23,111	36,261	56,427
% of Sales	88.8	90.3	86.7	85.1	85.9	84.9	84.5	84.2
EBITDA	413	409	937	1,683	2,542	4,107	6,651	10,619
Margin (%)	11.2	9.7	13.3	14.9	14.1	15.1	15.5	15.8
Depreciation	84	101	132	187	251	447	585	1,409
EBIT	330	308	805	1,496	2,290	3,660	6,066	9,210
Int. and Finance Charges	236	240	256	349	533	1,013	500	400
Other Income	19	40	41	114	559	1,070	1,294	2,064
PBT bef. EO Exp.	113	109	590	1,260	2,317	3,716	6,861	10,874
EO Items	0	0	0	0	0	0	0	0
PBT after EO Exp.	113	109	590	1,260	2,317	3,716	6,861	10,874
Total Tax	19	11	174	308	483	782	1,509	2,392
Tax Rate (%)	17.1	10.5	29.4	24.5	20.8	21.0	22.0	22.0
Minority Interest	0	0	0	0	0	0	0	0
Reported PAT	94	97	417	952	1,834	2,934	5,351	8,482
Adjusted PAT	94	97	417	952	1,834	2,934	5,351	8,482
Change (%)	-3.8	4.0	328.2	128.4	92.7	60.0	82.4	58.5
Margin (%)	2.5	2.3	5.9	8.5	10.2	10.8	12.5	12.7

Consolidated - Balance Sheet

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	68	68	462	581	639	641	641	641
Preference Capital	0	11	4	0	0	0	0	0
Total Reserves	959	1,308	1,560	9,009	24,230	27,762	33,113	41,595
Net Worth	1,027	1,387	2,026	9,590	24,869	28,403	33,754	42,235
Minority Interest	6	9	11	13	16	40	40	40
Total Loans	1,643	1,526	1,779	1,359	3,061	8,755	3,755	1,755
Deferred Tax Liabilities	79	52	68	77	102	130	130	130
Capital Employed	2,755	2,974	3,884	11,039	28,047	37,327	37,679	44,160
Gross Block	930	1,181	1,544	1,925	3,831	7,875	8,850	34,510
Less: Accum. Deprn.	382	483	615	802	1,054	1,501	2,086	3,496
Net Fixed Assets	547	698	929	1,123	2,777	6,374	6,764	31,015
Goodwill on Consolidation	23	23	23	23	152	141	141	141
Capital WIP	119	126	83	293	1,051	3,002	19,475	720
Total Investments	16	17	15	33	1,318	1,324	1,324	1,324
Current Investments	0	0	0	0	0	0	0	0
Curr. Assets, Loans&Adv.	3,075	3,330	5,173	12,715	27,354	35,571	25,730	42,668
Inventory	1,511	1,639	2,264	4,132	5,483	8,144	10,087	15,146
Account Receivables	937	1,218	1,977	2,271	3,556	5,746	7,054	11,021
Cash and Bank Balance	123	143	216	4,860	15,256	10,563	3,869	9,126
Loans and Advances	504	331	716	1,453	3,060	11,118	4,720	7,375
Curr. Liability & Prov.	1,027	1,219	2,340	3,148	4,605	9,085	15,756	31,708
Account Payables	921	954	1,641	2,229	3,610	6,829	8,430	13,208
Other Current Liabilities	76	226	648	857	920	2,130	7,111	18,164
Provisions	30	39	52	62	74	126	215	335
Net Current Assets	2,048	2,110	2,833	9,567	22,750	26,486	9,974	10,960
Misc Expenditure	0	0	0	0	0	0	0	0
Appl. of Funds	2,755	2,974	3,884	11,039	28,047	37,327	37,679	44,160

Keynes – Financials & Valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	13.8	14.3	9.0	16.4	28.7	45.8	83.5	132.4
Cash EPS	26.1	29.1	11.9	19.6	32.6	52.8	92.6	154.3
BV/Share	151.0	203.9	43.9	164.9	389.1	443.2	526.7	659.1
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)								
P/E	407.9	392.1	621.6	342.8	195.6	122.6	67.2	42.4
Cash P/E	215.2	192.6	472.4	286.4	172.0	106.3	60.6	36.4
P/BV	37.2	27.5	127.9	34.0	14.4	12.7	10.7	8.5
EV/Sales	10.8	9.4	36.9	28.7	19.2	13.1	8.4	5.3
EV/EBITDA	96.0	96.7	278.2	191.8	136.3	87.1	54.1	33.2
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	20.6	4.0	-4.6	-17.2	-32.7	-160.9	-38.8	87.3
Return Ratios (%)								
RoE	9.1	8.1	24.4	16.4	10.6	11.0	17.2	22.3
RoCE	10.8	11.2	17.8	16.5	11.6	11.5	15.4	21.6
RoIC	10.9	10.7	18.2	24.0	22.3	17.6	26.7	31.2
Working Capital Ratios								
Fixed Asset Turnover (x)	4.0	3.6	4.6	5.9	4.7	3.5	4.8	1.9
Asset Turnover (x)	1.0	1.0	1.1	0.8	0.6	0.6	0.8	0.9
Inventory (Days)	205	201	146	150	132	131	120	115
Debtor (Days)	106	93	83	69	59	62	60	60
Creditor (Days)	136	120	97	91	80	100	100	100
Leverage Ratio (x)								
Current Ratio	3.0	2.7	2.2	4.0	5.9	3.9	1.6	1.3
Interest Cover Ratio	1.4	1.3	3.1	4.3	4.3	3.6	12.1	23
Net Debt/Equity	1.5	1.0	0.8	-0.4	-0.5	-0.1	0.0	-0.2

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	113	109	590	1,260	2,317	3,716	6,861	10,874
Depreciation	84	101	132	187	251	447	585	1,409
Interest & Finance Charges	228	233	-11	-100	-27	1,013	-794	-1,664
Direct Taxes Paid	-19	-28	-22	-503	-483	-644	-1,509	-2,392
(Inc)/Dec in WC	44	-137	-743	-1,629	-1,358	-4,522	9,818	4,271
CF from Operations	451	277	-53	-784	701	10	14,960	12,498
Others	2	0	265	365	0	-834	0	0
CF from Operating incl EO	452	277	211	-419	701	-823	14,960	12,498
(Inc)/Dec in FA	-312	-250	-422	-581	-2,792	-9,487	-17,449	-6,905
Free Cash Flow	140	27	-211	-1,001	-2,091	-10,311	-2,489	5,593
(Pur)/Sale of Investments	205	2	-33	0	0	4,984	0	0
Others	8	7	11	-4,352	-12,261	957	1,294	2,064
CF from Investments	-99	-241	-445	-4,933	-15,052	-3,547	-16,154	-4,841
Issue of Shares	0	270	228	6,600	13,436	2	0	0
Inc/(Dec) in Debt	-118	-44	301	-336	1,702	5,694	-5,000	-2,000
Interest Paid	-236	-240	-256	-349	-533	-1,013	-500	-400
Dividend Paid	0	0	0	0	0	0	0	0
Others	0	-6	0	-371	-320	-33	0	0
CF from Fin. Activity	-354	-19	272	5,543	14,285	4,650	-5,500	-2,400
Inc/Dec of Cash	-1	17	38	191	-67	280	-6,695	5,257
Opening Balance	8	126	143	216	4,860	15,255	10,563	3,869
Other cash & cash equivalent	115	0	35	4,453	10,462	-4,972	0	0
Closing Balance	123	143	216	4,860	15,255	10,563	3,869	9,126

Avalon – Financials & Valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	6,419	6,905	8,407	9,447	8,672	10,981	14,056	17,992
Change (%)	NA	7.6	21.8	12.4	-8.2	26.6	28.0	28.0
RM Cost	4,128	4,574	5,552	6,067	5,545	7,055	9,066	11,515
Employees Cost	1,162	1,192	1,314	1,605	1,815	1,986	2,390	3,059
Other Expenses	484	478	566	647	685	836	1,012	1,241
Total Expenditure	5,774	6,243	7,432	8,319	8,046	9,876	12,468	15,815
% of Sales	90.0	90.4	88.4	88.1	92.8	89.9	88.7	87.9
EBITDA	645	662	975	1,128	626	1,105	1,588	2,177
Margin (%)	10.0	9.6	11.6	11.9	7.2	10.1	11.3	12.1
Depreciation	155	158	172	197	229	286	340	384
EBIT	490	504	803	931	397	819	1,248	1,793
Int. and Finance Charges	450	270	248	348	164	167	104	48
Other Income	113	54	309	144	148	215	281	360
PBT bef. EO Exp.	153	288	864	727	381	867	1,425	2,105
PBT after EO Exp.	0	0	0	0	0	0	0	0
Total Tax	153	288	864	727	381	867	1,425	2,105
Tax Rate (%)	30	58	183	202	101	233	363	530
Minority Interest	19.4	19.9	21.1	27.8	26.5	26.8	25.5	25.2
Reported PAT	8	16	50	0	0	0	0	0
Adjusted PAT	115	215	632	525	280	634	1,062	1,575
Change (%)	115	215	632	525	280	634	1,062	1,575
Margin (%)	NA	86.1	193.9	-16.9	-46.7	126.7	67.4	48.3

Consolidated - Balance Sheet

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	15	16	16	116	131	132	132	132
Preference Capital	356	388	388	0	0	0	0	0
Total Reserves	450	584	856	5,254	5,342	5,983	7,045	8,620
Net Worth	822	988	1,260	5,370	5,473	6,115	7,177	8,753
Minority Interest	-431	-317	0	0	0	0	0	0
Total Loans	2,388	2,775	2,789	3,063	1,642	1,800	800	400
Deferred Tax Liabilities	-263	0	0	0	15	19	19	19
Capital Employed	2,515	3,445	4,049	8,433	7,129	7,934	7,996	9,171
Gross Block								
Less: Accum. Deprn.	1,126	1,335	1,512	1,861	2,285	2,950	3,283	3,750
Net Fixed Assets	139	295	390	586	815	1,101	1,441	1,825
Goodwill on Consolidation	987	1,041	1,123	1,275	1,470	1,849	1,842	1,925
Capital WIP	0	0	0	0	0	0	0	0
Total Investments	27	0	20	153	196	104	271	304
Current Investments	24	0	0	0	755	349	349	349
Curr. Assets, Loans&Adv.	0	0	0	0	755	332	332	332
Inventory								
Account Receivables	3,197	4,084	4,738	10,375	6,886	8,096	8,858	10,650
Cash and Bank Balance	1,553	1,458	2,330	3,179	3,163	3,379	4,098	5,205
Loans and Advances	1,138	1,819	1,774	2,062	1,869	3,160	2,888	3,697
Curr. Liability & Prov.	266	335	101	4,222	1,065	1,015	888	668
Account Payables	241	472	532	912	789	542	984	1,080
Other Current Liabilities	1,719	1,680	1,831	3,370	2,178	2,465	3,325	4,057
Provisions	1,369	1,289	1,242	1,418	974	1,894	1,863	2,366
Net Current Assets	216	253	449	1,823	1,048	422	1,265	1,439
Misc Expenditure	134	138	141	130	156	149	197	252
Appl. of Funds	1,478	2,404	2,906	7,005	4,708	5,631	5,533	6,592

Avalon – Financials & Valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	2.0	3.7	10.9	9.1	4.3	9.6	16.1	23.8
Cash EPS	4.7	6.4	13.9	12.5	7.7	13.9	21.2	29.6
BV/Share	14.2	17.0	21.7	92.7	83.3	92.4	108.5	132.3
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)								
P/E	422.0	226.8	77.2	92.8	197.5	87.7	52.4	35.3
Cash P/E	180.1	130.9	60.7	67.5	108.6	60.5	39.7	28.4
P/BV	59.3	49.3	38.7	9.1	10.1	9.1	7.8	6.4
EV/Sales	7.9	7.4	6.1	5.0	6.4	5.1	3.9	3.1
EV/EBITDA	78.2	76.9	52.7	42.2	88.1	50.8	34.8	25.3
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	8.4	-2.4	-0.4	-7.0	-2.8	-3.2	10.5	-2.0
Return Ratios (%)								
RoE	14.1	23.8	56.2	15.8	5.2	10.9	16.0	19.8
RoCE	15.1	12.8	22.5	12.4	5.2	10.1	14.3	18.8
RoIC	21.4	17.7	20.2	17.7	6.4	10.4	14.4	18.7
Working Capital Ratios								
Fixed Asset Turnover (x)	5.7	5.6	5.9	5.6	4.2	4.2	4.5	5.1
Asset Turnover (x)	1.5	1.3	1.4	0.8	0.9	1.1	1.2	1.4
Inventory (Days)	98	120	125	166	209	169	165	165
Debtor (Days)	65	78	78	74	83	84	75	75
Creditor (Days)	87	106	83	80	79	74	75	75
Leverage Ratio (x)								
Current Ratio	1.9	2.4	2.6	3.1	3.2	3.3	2.7	2.6
Interest Cover Ratio	1.1	1.9	3.2	2.7	2.4	4.9	12.0	37.4
Net Debt/Equity	2.6	2.5	2.1	-0.2	0.0	0.1	-0.1	-0.1

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	153	288	856	727	381	867	1,425	2,105
Depreciation	155	158	180	197	229	286	340	384
Interest & Finance Charges	434	222	209	244	113	143	-177	-312
Direct Taxes Paid	-47	-35	-125	-189	-164	-194	-363	-530
(Inc)/Dec in WC	-121	-561	-805	-1,125	-414	-883	-30	-1,279
CF from Operations	574	72	315	-147	145	218	1,195	369
Others	83	-17	-158	13	28	32	0	0
CF from Operating incl EO	657	55	157	-133	173	250	1,195	369
(Inc)/Dec in FA	-170	-192	-177	-273	-355	-462	-500	-500
Free Cash Flow	487	-137	-21	-406	-182	-212	695	-131
(Pur)/Sale of Investments	-24	29	0	0	-1,121	955	0	0
Others	2	-104	-6	2	15	44	281	360
CF from Investments	-192	-267	-184	-271	-1,461	538	-219	-140
Issue of Shares	0	73	0	798	8	15	0	0
Inc/(Dec) in Debt	-296	461	158	128	-1,580	122	-1,000	-400
Interest Paid	-426	-217	-189	-283	-88	-111	-104	-48
Dividend Paid	-4	-37	-38	-37	-41	-52	0	0
Others	302	22	-138	3,915	-807	-497	0	0
CF from Fin. Activity	-424	301	-207	4,522	-2,508	-523	-1,104	-448
Inc/Dec of Cash	42	89	-234	4,118	-3,796	265	-128	-220
Opening Balance	204	246	335	101	4,219	423	1,015	888
Other cash & cash equivalent	20	0	0	3	643	328	0	0
Closing Balance	266	335	101	4,222	1,065	1,015	888	668

Cyient DLM – Financials & Valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	4,571	6,280	7,205	8,320	11,919	15,196	18,387	22,800
Change (%)	-4.9	37.4	14.7	15.5	43.2	27.5	21.0	24.0
RM Cost	3,649	4,953	5,440	6,452	9,200	11,082	12,871	15,892
Employees Cost	441	469	517	647	1,174	1,862	2,372	2,918
Other Expenses	344	399	409	344	435	800	1,195	1,368
Total Expenditure	4,434	5,821	6,365	7,442	10,809	13,745	16,438	20,178
% of Sales	97.0	92.7	88.3	89.4	90.7	90.4	89.4	88.5
EBITDA	137	460	840	878	1,110	1,452	1,949	2,622
Margin (%)	3.0	7.3	11.7	10.6	9.3	9.6	10.6	11.5
Depreciation	106	185	193	194	223	341	361	384
EBIT	31	275	647	684	887	1,111	1,588	2,238
Int. and Finance Charges	182	208	220	315	344	375	260	220
Other Income	78	89	79	63	278	262	288	316
PBT bef. EO Exp.	-72	156	507	432	821	997	1,616	2,335
EO Items	0	0	0	0	0	80	0	0
PBT after EO Exp.	-72	156	507	432	821	917	1,616	2,335
Total Tax	-5	38	109	114	209	236	407	588
Tax Rate (%)	7.2	24.2	21.6	26.5	25.5	25.8	25.2	25.2
Minority Interest	0	0	0	0	0	0	0	0
Reported PAT	-67	118	398	317	612	681	1,209	1,747
Adjusted PAT	-67	118	398	317	612	739	1,209	1,747
Change (%)	760.3	-276.3	236.0	-20.2	92.9	20.8	63.6	44.5
Margin (%)	-1.5	1.9	5.5	3.8	5.1	4.9	6.6	7.7

Consolidated - Balance Sheet

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	14	14	14	529	793	793	793	793
Total Reserves	243	363	757	1,450	8,297	8,701	9,911	11,658
Net Worth	257	377	771	1,979	9,090	9,494	10,704	12,451
Total Loans	3,080	2,790	3,369	3,145	1,336	2,438	1,438	938
Deferred Tax Liabilities	-62	-51	-39	0	0	0	0	0
Capital Employed	3,275	3,116	4,101	5,123	10,425	11,932	12,141	13,388
Gross Block	1,705	2,650	2,668	2,750	3,285	4,513	4,733	5,107
Less: Accum. Deprn.	674	824	977	1,171	1,394	1,734	2,095	2,479
Net Fixed Assets	1,032	1,826	1,692	1,579	1,891	2,779	2,638	2,628
Goodwill on Consolidation	30	30	30	30	30	681	681	681
Capital WIP	774	23	34	13	10	56	186	262
Total Investments	3	3	3	895	662	309	309	309
Curr. Assets, Loans&Adv.	4,034	4,517	5,971	8,529	13,440	13,115	15,491	18,373
Inventory	2,226	1,555	2,696	4,251	4,642	5,713	5,290	6,096
Account Receivables	546	2,264	1,523	1,617	2,259	3,474	3,468	4,301
Cash and Bank Balance	661	342	1,218	1,676	5,366	2,878	5,078	5,925
Loans and Advances	601	357	534	985	1,173	1,050	1,655	2,052
Curr. Liability & Prov.	2,599	3,284	3,629	5,924	5,607	5,007	7,164	8,865
Account Payables	1,205	1,928	1,932	2,853	3,200	2,499	3,310	4,086
Other Current Liabilities	1,330	1,262	1,564	2,973	2,297	2,326	3,677	4,560
Provisions	64	93	134	98	110	182	177	219
Net Current Assets	1,435	1,233	2,342	2,605	7,832	8,107	8,327	9,508
Appl. of Funds	3,274	3,116	4,101	5,123	10,425	11,932	12,141	13,388

Cyient DLM – Financials & Valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	-0.8	1.5	5.0	4.0	7.7	9.3	15.2	22.0
Cash EPS	0.5	3.8	7.4	6.4	10.5	13.6	19.8	26.9
BV/Share	3.2	4.7	9.7	25.0	114.6	119.7	135.0	157.0
Valuation (x)								
P/E	-527.1	299.0	89.0	111.5	57.8	47.9	29.2	20.2
Cash P/E	914.0	116.8	59.9	69.2	42.4	32.8	22.5	16.6
P/BV	137.6	93.9	45.9	17.9	3.9	3.7	3.3	2.8
EV/Sales	8.3	6.0	5.2	4.4	2.6	2.3	1.7	1.3
EV/EBITDA	275.4	82.3	44.7	42.0	28.2	24.1	16.3	11.6
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	-8.4	0.9	5.2	5.8	-13.2	-14.2	40.0	15.8
Return Ratios (%)								
RoE	-22.1	37.3	69.3	23.1	11.1	8.0	12.0	15.1
RoCE	3.8	8.5	15.6	11.9	11.2	9.1	11.7	15.0
RoIC	1.9	9.1	18.1	18.7	19.1	12.6	15.6	24.9
Working Capital Ratios								
Fixed Asset Turnover (x)	2.7	2.4	2.7	3.0	3.6	3.4	3.9	4.5
Asset Turnover (x)	1.4	2.0	1.8	1.6	1.1	1.3	1.5	1.7
Inventory (Days)	201	139	143	196	176	171	150	140
Debtor (Days)	70	82	96	69	59	69	69	69
Creditor (Days)	108	115	130	135	120	94	94	94
Leverage Ratio (x)								
Current Ratio	1.6	1.4	1.6	1.4	2.4	2.6	2.2	2.1
Interest Cover Ratio	0.2	1.3	2.9	2.2	2.6	3.0	6.1	10.2
Net Debt/Equity	9.4	6.5	2.8	0.7	-0.4	0.0	-0.3	-0.4

Consolidated - Cash Flow Statement

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
(INRm)								
OP/(Loss) before Tax	-67	118	398	317	821	917	1,616	2,335
Depreciation	106	185	193	194	223	341	361	384
Interest & Finance Charges	133	171	175	267	344	375	-28	-96
Direct Taxes Paid	3	1	-62	-168	-195	-257	-407	-588
(Inc)/Dec in WC	-105	-200	-329	-229	-1,676	-1,976	1,981	-334
CF from Operations	69	275	375	381	-483	-600	3,523	1,701
Others	93	74	111	158	-222	-24	0	0
CF from Operating incl EO	163	349	486	539	-705	-624	3,523	1,701
(Inc)/Dec in FA	-830	-274	-77	-76	-338	-500	-350	-450
Free Cash Flow	-667	75	409	463	-1,043	-1,124	3,173	1,251
(Pur)/Sale of Investments	-3	0	0	-892	0	0	0	0
Others	-51	265	-247	-450	-3,940	1,767	288	316
CF from Investments	-884	-9	-324	-1,418	-4,277	1,267	-62	-134
Issue of Shares	0	0	0	889	7,000	0	0	0
Inc/(Dec) in Debt	905	-336	534	-4	-1,647	323	-1,000	-500
Interest Paid	-183	-92	-73	-145	-192	-644	-260	-220
Dividend Paid	0	0	0	0	0	0	0	0
Others	0	-232	0	-19	-371	-266	0	0
CF from Fin. Activity	723	-660	461	721	4,790	-587	-1,260	-720
Inc/Dec of Cash	2	-320	622	-158	-193	55	2,201	847
Opening Balance	596	662	342	1,218	1,676	5,366	2,878	5,078
Other cash & cash equivalent	64	0	254	616	3,883	-2,544	0	0
Closing Balance	662	342	1,218	1,676	5,366	2,878	5,078	5,925

Syrma SGS – Financials & Valuations

Consolidated - Income Statement

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	8,621	8,858	12,667	20,484	31,538	37,862	51,113	66,447
Change (%)	143.5	2.8	43.0	61.7	54.0	20.1	35.0	30.0
RM Cost	5,847	6,276	9,408	15,405	25,069	29,258	39,511	51,430
Employees Cost	748	781	823	1,060	1,426	1,887	2,505	3,057
Other Expenses	731	786	1,148	2,142	3,059	3,696	5,009	6,512
Total Expenditure	7,325	7,842	11,380	18,606	29,554	34,841	47,024	60,999
% of Sales	85.0	88.5	89.8	90.8	93.7	92.0	92.0	91.8
EBITDA	1,295	1,016	1,287	1,878	1,984	3,021	4,089	5,449
Margin (%)	15.0	11.5	10.2	9.2	6.3	8.0	8.0	8.2
Depreciation	191	228	249	312	515	751	790	803
EBIT	1,105	789	1,038	1,566	1,469	2,270	3,299	4,646
Int. and Finance Charges	154	97	108	216	378	577	478	380
Other Income	183	177	178	437	587	699	920	997
PBT bef. EO Exp.	1,134	869	1,108	1,787	1,678	2,392	3,741	5,263
EO Items	0	0	0	0	-14	-21	0	0
PBT after EO Exp.	1,134	869	1,108	1,787	1,664	2,371	3,741	5,263
Total Tax	219	213	343	556	421	526	942	1,325
Tax Rate (%)	19.3	24.5	31.0	31.1	25.3	22.2	25.2	25.2
Minority Interest	31	25	42	38	170	147	206	257
Reported PAT	884	630	722	1,193	1,073	1,698	2,594	3,681
Adjusted PAT	884	630	722	1,193	1,087	1,719	2,594	3,681
Change (%)	321.5	-28.7	14.5	65.2	-8.9	58.2	50.9	41.9
Margin (%)	10.3	7.1	5.7	5.8	3.4	4.5	5.1	5.5

Consolidated - Balance Sheet

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	46	46	1,376	1,768	1,774	1,780	1,780	1,780
Preference Capital	47	0	0	0	0	0	0	0
Total Reserves	4,182	5,946	4,344	13,635	14,352	15,719	18,046	21,460
Net Worth	4,275	5,992	5,721	15,403	16,126	17,500	19,826	23,240
Minority Interest	2	6	108	26	644	749	954	1,211
Total Loans	1,205	1,029	2,183	3,468	5,763	6,112	5,412	4,712
Deferred Tax Liabilities	42	62	124	138	176	139	139	139
Capital Employed	5,523	7,089	8,136	19,035	22,710	24,499	26,331	29,303
Gross Block	2,089	2,264	3,233	4,821	8,134	9,077	9,964	10,882
Less: Accum. Deprn.	191	405	635	947	1,462	2,213	3,003	3,805
Net Fixed Assets	1,898	1,858	2,597	3,874	6,672	6,864	6,961	7,076
Goodwill on Consolidation	1,059	1,059	1,182	1,182	3,221	3,221	3,221	3,221
Capital WIP	12	0	408	253	168	609	522	604
Total Investments	301	1,316	410	8,500	419	594	594	594
Current Investments	0	0	0	780	355	514	514	514
Curr. Assets, Loans&Adv.	4,591	5,365	6,945	11,603	26,414	30,758	38,722	48,603
Inventory	1,419	1,789	2,913	5,874	10,043	8,219	11,203	14,564
Account Receivables	1,804	2,084	2,722	4,032	9,301	14,775	19,605	25,487
Cash and Bank Balance	780	729	369	544	856	2,958	1,781	1,243
Loans and Advances	588	763	940	1,151	6,215	4,807	6,134	7,309
Curr. Liability & Prov.	2,338	2,509	3,407	6,377	14,185	17,548	23,689	30,796
Account Payables	1,707	1,848	2,405	4,881	12,232	15,744	21,254	27,630
Other Current Liabilities	506	554	857	1,362	1,778	1,597	2,156	2,803
Provisions	125	108	145	134	174	207	279	362
Net Current Assets	2,253	2,856	3,538	5,226	12,230	13,211	15,033	17,807
Misc Expenditure	0	0	0	0	0	0	0	0
Appl. of Funds	5,523	7,089	8,136	19,035	22,710	24,499	26,331	29,303

Syrma SGS – Financials & Valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	6.4	4.6	5.2	6.7	6.1	9.7	14.6	20.7
Cash EPS	7.8	6.2	7.1	8.5	9.0	13.9	19.0	25.2
BV/Share	31.1	43.5	41.6	87.1	90.9	98.3	111.4	130.5
DPS	0.0	0.0	0.0	0.0	1.5	1.5	1.5	1.5
Payout (%)	0.0	0.0	0.0	0.0	24.8	15.7	10.3	7.3
Valuation (x)								
P/E	79.6	111.5	97.4	75.7	83.4	52.9	35.1	24.7
Cash P/E	65.4	82.0	72.4	60.0	56.6	36.8	26.9	20.3
P/BV	16.5	11.7	12.3	5.9	5.6	5.2	4.6	3.9
EV/Sales	8.2	8.0	5.7	4.5	3.0	2.5	1.9	1.4
EV/EBITDA	54.6	69.5	56.1	49.3	48.3	31.2	23.2	17.5
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3
FCF per share	7.8	1.3	-7.5	-12.1	-25.4	0.2	-3.7	-1.1
Return Ratios (%)								
RoE	35.8	12.3	12.3	11.3	6.9	10.2	13.9	17.1
RoCE	29.4	11.7	11.2	10.3	7.5	10.2	12.9	15.9
RoIC	31.1	12.6	11.9	12.9	7.1	8.5	11.3	13.8
Working Capital Ratios								
Fixed Asset Turnover (x)	4.1	3.9	3.9	4.2	3.9	4.2	5.1	6.1
Asset Turnover (x)	1.6	1.2	1.6	1.1	1.4	1.5	1.9	2.3
Inventory (Days)	60	74	84	105	116	79	80	80
Debtor (Days)	76	86	78	72	108	142	140	140
Creditor (Days)	72	76	69	87	142	152	152	152
Leverage Ratio (x)								
Current Ratio	2.0	2.1	2.0	1.8	1.9	1.8	1.6	1.6
Interest Cover Ratio	7.2	8.1	9.6	7.3	3.9	3.9	6.9	12.2
Net Debt/Equity	0.1	0.1	0.3	0.1	0.3	0.2	0.2	0.1

Consolidated - Cash Flow Statement

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	1,134	869	1,108	1,787	1,664	2,371	3,741	5,263
Depreciation	191	228	249	312	515	751	790	803
Interest & Finance Charges	117	52	54	-222	378	585	-442	-617
Direct Taxes Paid	-207	-220	-289	-556	-540	-607	-942	-1,325
(Inc)/Dec in WC	301	-499	-1,212	-2,140	-2,804	-934	-3,000	-3,311
CF from Operations	1,535	430	-90	-818	-786	2,165	148	813
Others	23	-58	-36	115	-350	-400	0	0
CF from Operating incl EO	1,558	371	-126	-703	-1,136	1,765	148	813
(Inc)/Dec in FA	-479	-187	-901	-1,433	-3,370	-1,726	-800	-1,000
Free Cash Flow	1,079	184	-1,027	-2,136	-4,506	39	-652	-187
(Pur)/Sale of Investments	-20	-51	11	0	-2,300	605	0	0
Others	42	-888	-2,844	-7,711	5,388	69	920	997
CF from Investments	-457	-1,127	-3,734	-9,144	-282	-1,052	120	-3
Issue of Shares	0	331	2,715	9,682	0	0	0	0
Inc/(Dec) in Debt	-416	-179	1,159	1,285	2,295	330	-700	-700
Interest Paid	-119	-70	-70	-216	-378	0	-478	-380
Dividend Paid	-20	0	0	0	0	-266	-267	-267
Others	-37	622	-303	-730	-187	1,326	0	0
CF from Fin. Activity	-593	705	3,500	10,022	1,730	1,389	-1,445	-1,347
Inc/Dec of Cash	508	-51	-360	175	312	2,102	-1,177	-537
Opening Balance	143	780	729	369	544	856	2,958	1,781
Other cash & cash equivalent	130	0	0	0				
Closing Balance	780	729	369	544	856	2,958	1,781	1,243

Data Patterns – Financials & Valuations

Consolidated - Income Statement							(INRm)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	1,561	2,240	3,109	4,535	5,198	7,084	8,876	11,139
Change (%)	19.1	43.5	38.8	45.9	14.6	36.3	25.3	25.5
RM Cost	561	704	861	1,709	1,637	2,761	3,461	4,288
Employees Cost	411	472	604	795	1,003	1,141	1,429	1,782
Other Expenses	157	144	233	312	342	432	621	780
Total Expenditure	1,129	1,320	1,698	2,816	2,982	4,334	5,512	6,850
% of Sales	72.4	58.9	54.6	62.1	57.4	61.2	62.1	61.5
EBITDA	432	920	1,410	1,718	2,217	2,750	3,364	4,288
Margin (%)	27.6	41.1	45.4	37.9	42.6	38.8	37.9	38.5
Depreciation	55	56	66	84	162	139	207	248
EBIT	377	864	1,344	1,634	2,055	2,611	3,157	4,040
Int. and Finance Charges	133	145	110	77	93	121	115	109
Other Income	41	26	40	92	460	463	666	835
PBT bef. EO Exp.	284	745	1,274	1,649	2,422	2,953	3,708	4,767
EO Items	0	0	0	0	0	0	0	0
PBT after EO Exp.	284	745	1,274	1,649	2,422	2,953	3,708	4,767
Total Tax	74	190	334	409	605	735	923	1,187
Tax Rate (%)	26.0	25.4	26.2	24.8	25.0	24.9	24.9	24.9
Minority Interest	0	0	0	0	0	0	0	0
Reported PAT	211	556	940	1,240	1,817	2,218	2,785	3,580
Adjusted PAT	211	556	940	1,240	1,817	2,218	2,785	3,580
Change (%)	173.4	163.9	69.1	31.9	46.6	22.1	25.5	28.6
Margin (%)	13.5	24.8	30.2	27.3	35.0	31.3	31.4	32.1

Consolidated - Balance Sheet							(INRm)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	17	17	104	112	112	112	112	112
Preference Capital	0	0	0	0	0	0	0	0
Total Reserves	1,518	2,062	5,641	11,559	13,130	14,970	17,699	21,223
Net Worth	1,535	2,079	5,745	11,671	13,242	15,082	17,811	21,335
Minority Interest	0	0	0	0	0	0	0	0
Total Loans	606	372	92	7	0	0	0	0
Deferred Tax Liabilities	8	9	-8	0	0	225	225	225
Capital Employed	2,148	2,460	5,830	11,678	13,242	15,307	18,035	21,559
Gross Block	447	425	634	1,176	1,629	2,717	3,195	3,890
Less: Accum. Deprn.	113	93	159	243	405	544	751	999
Net Fixed Assets	334	332	475	933	1,224	2,173	2,444	2,891
Goodwill on Consolidation	0	0	0	0	0	0	0	0
Capital WIP	0	0	173	14	481	128	401	455
Total Investments	0	0	0	557	2,622	3,266	3,266	3,266
Current Investments	0	0	0	557	2,622	3,266	3,266	3,266
Curr. Assets, Loans&Adv.	2,620	2,954	6,411	12,847	12,591	12,824	15,857	19,864
Inventory	794	737	1,198	1,930	2,668	3,185	3,793	4,700
Account Receivables	1,156	1,559	1,983	3,825	3,988	5,964	7,052	8,850
Cash and Bank Balance	15	88	1,771	5,445	3,927	1,264	1,990	2,523
Loans and Advances	655	569	1,460	1,647	2,009	2,411	3,021	3,792
Curr. Liability & Prov.	805	826	1,230	2,671	3,676	3,084	3,931	4,916
Account Payables	173	120	416	431	501	838	1,051	1,302
Other Current Liabilities	506	560	570	2,107	3,028	2,073	2,663	3,342
Provisions	126	146	244	134	146	174	218	273
Net Current Assets	1,815	2,128	5,182	10,175	8,916	9,740	11,926	14,948
Misc Expenditure	0	0	0	0	0	0	0	0
Appl. of Funds	2,148	2,460	5,830	11,678	13,242	15,307	18,035	21,559

Data Patterns – Financials & Valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	24.8	65.4	18.1	22.1	32.4	39.6	49.7	63.9
Cash EPS	31.2	71.9	19.4	23.6	35.3	42.1	53.4	68.4
BV/Share	180.6	244.6	110.7	208.4	236.5	269.3	318.1	381.0
DPS	0.0	0.0	0.0	0.7	0.9	1.1	1.0	1.0
Payout (%)	0.0	0.0	0.0	3.2	2.8	2.8	2.0	1.6
Valuation (x)								
P/E	118.5	44.9	162.1	132.6	90.5	74.1	59.0	45.9
Cash P/E	94.0	40.8	151.4	124.1	83.1	69.7	54.9	42.9
P/BV	16.3	12.0	26.5	14.1	12.4	10.9	9.2	7.7
EV/Sales	16.4	11.3	48.5	34.9	30.4	22.6	17.9	14.2
EV/EBITDA	59.2	27.4	106.8	92.2	71.2	58.1	47.3	37.0
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	14.4	45.2	2.3	-9.9	8.5	-22.5	4.1	-2.5
Return Ratios (%)								
RoE	14.7	30.7	24.0	14.2	14.6	15.7	16.9	18.3
RoCE	15.2	28.9	24.6	14.8	15.1	16.3	17.5	18.7
RoIC	13.7	28.6	31.7	25.7	26.0	23.3	20.6	21.9
Working Capital Ratios								
Fixed Asset Turnover (x)	3.5	5.3	4.9	3.9	3.2	2.6	2.8	2.9
Asset Turnover (x)	0.7	0.9	0.5	0.4	0.4	0.5	0.5	0.5
Inventory (Days)	517	382	508	412	595	421	400	400
Debtor (Days)	270	254	233	308	280	307	290	290
Creditor (Days)	112	62	176	92	112	111	111	111
Leverage Ratio (x)								
Current Ratio	3.3	3.6	5.2	4.8	3.4	4.2	4.0	4.0
Interest Cover Ratio	2.8	6.0	12.2	21.2	22.0	21.6	27.5	37.1
Net Debt/Equity	0.4	0.1	-0.3	-0.5	-0.5	-0.3	-0.3	-0.3

Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	284	745	1,274	1,649	2,422	2,953	3,708	4,767
Depreciation	55	56	66	84	162	139	207	248
Interest & Finance Charges	108	123	70	-15	-367	121	-551	-726
Direct Taxes Paid	-28	-190	-284	-409	-605	-706	-923	-1,187
(Inc)/Dec in WC	-283	-299	-624	-1,482	-218	-2,976	-1,459	-2,489
CF from Operations	136	435	503	-173	1,394	-468	981	613
Others	-2	-1	0	0	0	-431	0	0
CF from Operating incl EO	134	434	503	-173	1,394	-899	981	613
(Inc)/Dec in FA	-12	-50	-382	-383	-920	-359	-750	-750
Free Cash Flow	123	384	121	-555	473	-1,257	231	-137
(Pur)/Sale of Investments	0	0	0	0	0	1,769	0	0
Others	26	137	-796	-1	-1,319	-520	666	835
CF from Investments	14	88	-1,178	-384	-2,239	890	-84	85
Issue of Shares	0	0	3,000	0	0	0	0	0
Inc/(Dec) in Debt	-132	-300	-283	-85	-7	0	0	0
Interest Paid	0	-145	-89	-77	-93	-115	-115	-109
Dividend Paid	-4	-3	-111	-39	-50	-364	-56	-56
Others	0	0	-159	4,432	-522	-2,176	0	0
CF from Fin. Activity	-136	-449	2,359	4,231	-673	-2,655	-171	-165
Inc/Dec of Cash	12	73	1,683	3,675	-1,518	-2,663	726	533
Opening Balance	3	15	88	1,771	5,445	3,927	1,264	1,990
Closing Balance	15	88	1,771	5,445	3,927	1,264	1,990	2,523

Dixon – Financials & Valuations

Consolidated - Income Statement

(INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	44,001	64,482	106,971	121,920	176,909	388,601	532,357	671,868
Change (%)	47.4	46.5	65.9	14.0	45.1	119.7	37.0	26.2
Raw Materials	38,602	57,697	97,792	110,207	160,390	358,328	490,886	619,528
Gross Profit	5,399	6,785	9,178	11,713	16,520	30,273	41,472	52,340
Employee Cost	1,180	1,371	1,978	2,517	3,327	5,674	7,773	9,810
Other Expenses	1,989	2,548	3,409	4,069	6,217	9,523	13,503	15,929
Total Expenditure	41,771	61,616	103,180	116,793	169,933	373,525	512,161	645,268
% of Sales	94.9	95.6	96.5	95.8	96.1	96.1	96.2	96.0
EBITDA	2,231	2,866	3,791	5,128	6,976	15,076	20,196	26,600
Margin (%)	5.1	4.4	3.5	4.2	3.9	3.9	3.8	4.0
Depreciation	365	437	840	1,146	1,619	2,810	3,602	4,394
EBIT	1,865	2,429	2,952	3,981	5,357	12,266	16,594	22,206
Int. and Finance Charges	350	274	442	606	747	1,544	1,667	1,748
Other Income	52	16	38	56	226	202	914	1,638
PBT bef. EO Exp.	1,568	2,170	2,548	3,432	4,836	10,924	15,841	22,096
EO Items	0	0	0	0	0	4,600	0	0
PBT after EO Exp.	1,568	2,170	2,548	3,432	4,836	15,524	15,841	22,096
Total Tax	363	572	644	897	1,189	3,372	3,864	5,376
Tax Rate (%)	23.1	26.4	25.3	26.1	24.6	21.7	24.4	24.3
Profit share of associates/JV	0	0	-1	16	102	174	191	210
Minority Interest	0	0	2	-4	72	1,370	2,006	2,374
Reported PAT	1,205	1,598	1,902	2,555	3,677	10,955	10,162	14,557
Adjusted PAT	1,205	1,598	1,902	2,555	3,677	7,059	10,162	14,557
Change (%)	90.2	32.6	19.0	34.4	43.9	92.0	44.0	43.2
Margin (%)	2.7	2.5	1.8	2.1	2.1	1.8	1.9	2.2

Consolidated - Balance Sheet

(INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	116	117	119	119	120	121	121	121
Total Reserves	5,298	7,256	9,849	12,730	16,829	29,982	39,662	53,736
Net Worth	5,413	7,373	9,968	12,849	16,949	30,102	39,782	53,857
Minority Interest	0	0	6	-3	276	4,591	6,598	8,971
Total Loans	828	1,513	4,580	1,826	1,550	2,023	2,023	2,023
Deferred Tax Liabilities	148	184	201	224	240	980	980	980
Capital Employed	6,389	9,070	14,754	14,897	19,015	37,696	49,383	65,831
Gross Block	3,982	5,269	9,586	12,291	20,633	27,732	36,232	43,232
Less: Accum. Deprn.	825	1,170	1,815	2,641	3,958	6,256	9,294	13,069
Net Fixed Assets	3,157	4,099	7,771	9,649	16,675	21,476	26,938	30,163
Goodwill on Consolidation	82	82	303	303	303	570	570	570
Capital WIP	96	724	224	1,197	683	2,570	2,570	2,570
Total Investments	0	953	1,410	442	200	5,356	5,356	5,356
Curr. Assets, Loans&Adv.	13,635	22,600	33,064	35,203	52,034	137,606	190,365	248,811
Inventory	4,978	7,433	11,557	9,579	16,950	39,924	54,693	69,026
Account Receivables	5,151	10,891	13,564	17,155	23,179	69,655	95,422	120,429
Cash and Bank Balance	1,002	689	1,823	2,292	2,087	2,635	7,311	19,016
Loans and Advances	0	25	4	0	20	0	0	0
Other Current Asset	2,504	3,563	6,116	6,178	9,799	25,392	32,939	40,340
Curr. Liability & Prov.	10,580	19,387	28,017	31,898	50,881	129,881	176,415	221,638
Account Payables	9,391	17,097	23,137	24,519	40,652	108,837	149,099	188,172
Other Current Liabilities	1,081	2,146	4,664	7,121	9,952	20,768	26,937	32,988
Provisions	109	144	216	258	277	277	379	478
Net Current Assets	3,054	3,213	5,047	3,306	1,153	7,725	13,950	27,173
Appl. of Funds	6,389	9,070	14,754	14,897	19,015	37,696	49,383	65,832

Dixon – Financials & Valuations

Ratios

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	20.6	27.3	32.0	42.9	61.5	117.2	168.7	241.6
Cash EPS	26.8	34.7	46.2	62.1	88.6	163.8	228.4	314.5
BV/Share	92.4	125.9	168.0	215.7	283.4	499.6	660.3	893.9
DPS	1.2	1.0	2.0	3.0	3.0	8.0	8.0	8.0
Payout (%)	5.7	3.7	6.3	7.0	4.9	7.6	4.7	3.3
Valuation (x)								
P/E	680.7	513.2	437.0	326.4	227.7	119.5	83.0	58.0
Cash P/E	522.3	403.0	303.2	225.3	158.1	85.5	61.3	44.5
P/BV	151.5	111.2	83.4	64.9	49.4	28.0	21.2	15.7
EV/Sales	18.6	12.7	7.8	6.8	4.7	2.2	1.6	1.2
EV/EBITDA	367.6	286.5	219.9	162.6	120.0	55.9	41.5	31.1
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1
FCF per share	22.1	0.4	-24.4	46.3	2.6	42.2	91.1	204.2
Return Ratios (%)								
RoE	26.2	25.0	21.9	22.4	24.7	30.0	29.1	31.1
RoCE	25.9	23.8	19.1	20.4	25.4	38.6	35.8	36.9
RoIC	28.8	29.8	24.5	26.4	29.9	44.5	40.9	46.0
Working Capital Ratios								
Fixed Asset Turnover (x)	11.0	12.2	11.2	9.9	8.6	14.0	14.7	15.5
Asset Turnover (x)	6.9	7.1	7.3	8.2	9.3	10.3	10.8	10.2
Inventory (Days)	41	42	39	29	35	37	37	37
Debtor (Days)	43	62	46	51	48	65	65	65
Creditor (Days)	78	97	79	73	84	102	102	102
Leverage Ratio (x)								
Current Ratio	1.3	1.2	1.2	1.1	1.0	1.1	1.1	1.1
Interest Cover Ratio	5.3	8.9	6.7	6.6	7.2	7.9	10.0	12.7
Net Debt/Equity	-0.0	-0.0	0.1	-0.1	-0.0	-0.2	-0.3	-0.4

Consolidated - Cashflow Statement

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
(INR m)								
OP/(Loss) before Tax	1,568	2,170	2,546	3,452	4,867	14,328	14,026	19,932
Depreciation	365	437	840	1,146	1,619	2,810	3,602	4,394
Interest & Finance Charges	350	274	442	606	747	1,544	1,667	1,748
Direct Taxes Paid	-429	-549	-540	-820	-1,218	-2,760	-3,864	-5,376
(Inc)/Dec in WC	423	-743	-641	2,764	-88	-1,816	-1,439	-1,397
CF from Operations	2,277	1,590	2,646	7,148	5,927	14,106	13,991	19,302
Others	97	111	81	109	-83	-2,608	0	0
CF from Operating incl EO	2,374	1,701	2,728	7,258	5,843	11,498	13,991	19,302
(Inc)/Dec in FA	-1,081	-1,680	-4,174	-4,502	-5,686	-8,956	-8,500	-7,000
Free Cash Flow	1,293	22	-1,446	2,755	157	2,542	5,491	12,302
(Pur)/Sale of Investments	-118	-978	-446	992	346	-3,208	0	0
Others	28	8	-25	-45	31	-125	-110	-121
CF from Investments	-1,171	-2,649	-4,645	-3,556	-5,309	-12,289	-8,610	-7,121
Issue of Shares	457	269	642	336	469	1,399	0	0
Inc/(Dec) in Debt	-570	688	3,026	-2,776	-276	583	0	0
Interest Paid	-378	-322	-567	-737	-494	-1,219	-1,667	-1,748
Dividend Paid	-83	0	-59	-119	-179	-329	-482	-482
Others	6	0	0	0	-220	-700	2,006	2,374
CF from Fin. Activity	-568	635	3,043	-3,296	-700	-266	-142	144
Inc/Dec of Cash	634	-313	1,126	406	-166	-1,057	5,239	12,325
Opening Balance	367	1,002	689	1,823	2,292	2,086	2,635	7,311
Other Bank Balances	0	0	8	63	-40	1,606	-563	-620
Closing Balance	1,002	689	1,823	2,292	2,086	2,635	7,311	19,016

Amber – Financials & Valuation

Consolidated - Income Statement

(INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	39,628	30,305	42,064	69,271	67,293	99,730	116,928	143,332
Change (%)	44.0	-23.5	38.8	64.7	-2.9	48.2	17.2	22.6
Raw Materials	33,017	25,135	35,297	58,678	54,999	81,856	95,971	117,643
Gross Profit	6,611	5,170	6,767	10,593	12,293	17,875	20,957	25,689
Employee Cost	1,063	1,021	1,500	2,116	2,572	3,246	3,508	4,300
Other Expenses	2,455	1,947	2,514	4,298	4,802	6,995	7,870	8,980
Total Expenditure	36,535	28,102	39,310	65,092	62,374	92,096	107,348	130,922
% of Sales	92.2	92.7	93.5	94.0	92.7	92.3	91.8	91.3
EBITDA	3,093	2,203	2,754	4,179	4,919	7,634	9,579	12,410
Margin (%)	7.8	7.3	6.5	6.0	7.3	7.7	8.2	8.7
Depreciation	848	923	1,079	1,391	1,865	2,283	2,443	2,674
EBIT	2,245	1,280	1,675	2,788	3,054	5,351	7,137	9,735
Int. and Finance Charges	419	410	464	1,118	1,670	2,087	2,403	2,411
Other Income	82	331	332	527	553	736	792	945
PBT bef. EO Exp.	1,907	1,201	1,543	2,197	1,937	3,999	5,526	8,270
EO Items	0	0	0	0	0	0	0	0
PBT after EO Exp.	1,907	1,201	1,543	2,197	1,937	3,999	5,526	8,270
Total Tax	266	369	429	559	519	1,188	1,710	2,608
Tax Rate (%)	13.9	30.7	27.8	25.4	26.8	29.7	31.0	31.5
MI & Profit/Loss of Asso. Cos.	57	17	21	66	89	376	284	242
Reported PAT	1,584	816	1,092	1,572	1,329	2,436	3,532	5,421
Adjusted PAT	1,584	816	1,092	1,572	1,329	2,436	3,532	5,421
Change (%)	69.1	-48.5	33.8	44.0	-15.5	83.3	45.0	53.5
Margin (%)	4.0	2.7	2.6	2.3	2.0	2.4	3.0	3.8

Consolidated - Balance Sheet

(INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	314	337	337	337	337	338	338	338
Total Reserves	10,970	15,704	17,005	18,751	20,307	22,520	26,052	31,472
Net Worth	11,284	16,041	17,342	19,088	20,644	22,858	26,390	31,810
Minority Interest	348	365	387	452	518	245	329	421
Total Loans	3,205	3,495	10,318	13,437	14,332	19,400	19,400	19,400
Deferred Tax Liabilities	678	769	954	947	1,348	1,749	1,749	1,749
Capital Employed	15,515	20,670	29,001	33,924	36,841	44,253	47,868	53,380
Gross Block	13,465	14,683	18,037	25,621	31,309	35,305	38,805	42,305
Less: Accum. Deprn.	3,630	4,466	5,335	6,556	8,333	10,531	12,866	15,421
Net Fixed Assets	9,836	10,218	12,702	19,065	22,977	24,774	25,940	26,885
Goodwill on Consolidation	1,223	1,223	1,457	1,425	3,609	3,609	3,609	3,609
Capital WIP	118	433	1,282	503	908	1,977	1,977	1,977
Total Investments	0	1,081	2,254	1,934	2,173	2,515	2,515	2,515
Curr. Assets, Loans&Adv.	17,813	22,892	31,401	39,475	36,236	51,390	60,280	74,609
Inventory	6,557	7,163	8,408	10,913	8,408	16,551	19,405	23,787
Account Receivables	8,542	10,690	13,149	17,631	15,693	17,501	20,519	25,152
Cash and Bank Balance	1,203	2,899	5,626	5,594	6,913	7,268	9,161	12,922
Loans and Advances	293	321	18	39	49	356	417	511
Other Current Asset	1,218	1,818	4,200	5,297	5,173	9,715	10,779	12,238
Curr. Liability & Prov.	13,474	15,175	20,095	28,478	29,060	40,012	46,452	56,214
Account Payables	11,058	13,169	17,021	23,039	21,671	31,703	37,170	45,564
Other Current Liabilities	2,288	1,864	2,888	5,216	7,090	7,973	8,888	10,167
Provisions	128	141	186	223	300	336	394	483
Net Current Assets	4,339	7,717	11,306	10,997	7,175	11,378	13,828	18,396
Appl. of Funds	15,515	20,670	29,001	33,924	36,841	44,253	47,868	53,381

Amber – Financials & Valuations

Ratios

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	50.4	24.2	32.4	46.7	39.4	72.0	104.4	160.3
Cash EPS	77.3	51.6	64.4	87.9	94.8	139.5	176.6	239.3
BV/Share	358.8	476.1	514.7	566.5	612.7	675.8	780.2	940.5
DPS	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)								
P/E	127.5	265.2	198.2	137.6	162.8	89.2	61.5	40.1
Cash P/E	83.0	124.4	99.7	73.0	67.7	46.0	36.4	26.8
P/BV	17.9	13.5	12.5	11.3	10.5	9.5	8.2	6.8
EV/Sales	5.1	7.2	5.3	3.2	3.3	2.3	1.9	1.6
EV/EBITDA	65.9	98.5	80.3	53.7	45.5	30.0	23.7	18.0
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	46.8	14.8	-49.6	-98.8	168.3	45.9	133.4	189.5
Return Ratios (%)								
RoE	15.0	6.0	6.5	8.6	6.7	11.2	14.3	18.6
RoCE	15.0	6.6	6.1	8.2	7.8	11.1	12.4	15.1
RoIC	14.7	5.8	6.7	9.1	8.5	12.7	14.8	19.0
Working Capital Ratios								
Fixed Asset Turnover (x)	2.9	2.1	2.3	2.7	2.1	2.8	3.0	3.4
Asset Turnover (x)	2.6	1.5	1.5	2.0	1.8	2.3	2.4	2.7
Inventory (Days)	60	86	73	58	46	61	61	61
Debtor (Days)	79	129	114	93	85	64	64	64
Creditor (Days)	102	159	148	121	118	116	116	116
Leverage Ratio (x)								
Current Ratio	1.3	1.5	1.6	1.4	1.2	1.3	1.3	1.3
Interest Cover Ratio	5.4	3.1	3.6	2.5	1.8	2.6	3.0	4.0
Net Debt/Equity	0.2	0.0	0.1	0.3	0.3	0.4	0.3	0.1

Consolidated - Cashflow Statement

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
(INR m)								
OP/(Loss) before Tax	1,907	1,201	1,543	2,197	1,913	3,700	5,326	8,120
Depreciation	848	923	1,079	1,391	1,865	2,283	2,443	2,674
Interest & Finance Charges	419	406	464	1,118	1,670	2,087	2,403	2,411
Direct Taxes Paid	-488	-79	-539	-539	-461	-710	-1,710	-2,608
(Inc)/Dec in WC	44	-80	-62	-582	5,032	272	-448	-688
CF from Operations	2,731	2,371	2,485	3,585	10,019	7,632	8,013	9,909
Others	151	-162	-77	-379	-371	-523	0	0
CF from Operating incl EO	2,882	2,210	2,407	3,206	9,648	7,109	8,013	9,909
(Inc)/Dec in FA	-1,411	-1,711	-4,077	-6,535	-3,977	-5,556	-3,500	-3,500
Free Cash Flow	1,471	499	-1,670	-3,329	5,671	1,553	4,513	6,409
(Pur)/Sale of Investments	-1,672	-1,568	-1,542	210	788	-159	0	0
Others	-183	-1,531	-1,277	1,437	-7,156	-3,814	-109	-118
CF from Investments	-3,266	-4,810	-6,896	-4,888	-10,345	-9,529	-3,609	-3,618
Issue of Shares	0	3,936	0	0	0	353	0	0
Inc/(Dec) in Debt	1,209	161	6,031	3,120	589	5,067	0	0
Interest Paid	-430	-372	-430	-1,097	-1,567	-1,970	-2,403	-2,411
Dividend Paid	-121	0	0	0	0	0	0	0
Others	-23	-24	-46	-96	-238	-221	0	0
CF from Fin. Activity	634	3,700	5,555	1,928	-1,216	3,229	-2,403	-2,411
Inc/Dec of Cash	250	1,099	1,066	246	-1,913	809	2,001	3,881
Opening Balance	450	700	1,920	2,986	3,232	1,319	7,268	9,161
Other Bank Balances	503	1,100	2,640	2,363	5,594	5,140	-108	-119
Closing Balance	1,203	2,899	5,626	5,594	6,913	7,268	9,161	12,922

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh

Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies)

in the past 12 months.

9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of

Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.